{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:08:29Z","timestamp":1780337309225,"version":"3.54.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2024GXNSFAA010093"],"award-info":[{"award-number":["2024GXNSFAA010093"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    This study aimed to analyze drug adverse events, identify high-risk medications associated with cardiovascular disease (CVD), and provide evidence for clinical medication safety.\n                    <jats:bold>Methods:<\/jats:bold>\n                    We conducted a retrospective analysis of the FAERS database (2004Q1\u20132024Q4) using nine CVD-related terms from MedDRA 27.0. Four signal detection methods\u2014PRR, ROR, BCPNN, and MGPS\u2014were employed to identify significant drug\u2014event associations.\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 1,560,242 CVD-related reports were included. Rofecoxib, phenylpropanolamine and rosiglitazone were strongly associated with CVD, with ROR values of 73.4 (95% CI: 71.16\u201375.7), 66.8 (95% CI: 23.25\u2013191.94), and 58.69 (95% CI: 57.68\u201359.76), respectively. These drugs have since been withdrawn or restricted. Subgroup analysis revealed gender and age differences in CVD risk: testosterone related drugs may be associated with cardiovascular disease risk in elderly and male patients, while alendronic acid may be associated with increased cardiovascular risk in female patients. These preliminary associations may stem from mixed indications rather than direct effects of the drugs. Validate and quantify in the real world doxorubicin and other anticancer agents are correlated with cardiotoxicity in children known risks. Additionally, potential associations with previously unreported CVD risks were suggested for paricalcitol, busulfan, gemtuzumab ozogamicin, clofarabine, and clofazimine, which warrant further attention.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study showed that some drugs were significantly associated with CVD, and some of them were newly discovered signals. These findings provide a basis for the generation of new hypotheses about the cardiovascular risk of drugs, but the causal relationship needs to be confirmed by further research.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0349218","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:29:21Z","timestamp":1780334961000},"page":"e0349218","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of drug-related cardiovascular risks: A comprehensive analysis using the FAERS database (2004\u20132024)"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8052-9528","authenticated-orcid":true,"given":"Naishen","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5282-2333","authenticated-orcid":true,"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangnan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"pone.0349218.ref001","doi-asserted-by":"crossref","first-page":"117374","DOI":"10.1016\/j.biopha.2024.117374","article-title":"Cellular and molecular biology of posttranslational modifications in cardiovascular disease","volume":"179","author":"L Zhu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"pone.0349218.ref002","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"SS Martin","year":"2025","journal-title":"Circulation"},{"issue":"6","key":"pone.0349218.ref003","doi-asserted-by":"crossref","DOI":"10.1097\/JOM.0000000000000738","article-title":"Impact of a comprehensive workplace hand hygiene program on employer health care insurance claims and costs, absenteeism, and employee perceptions and practices","volume":"58","author":"JW Arbogast","year":"2016","journal-title":"J Occup Environ Med"},{"key":"pone.0349218.ref004","doi-asserted-by":"crossref","first-page":"108480","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"S Hummelgaard","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"3","key":"pone.0349218.ref005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31083\/j.fbl2703105","article-title":"Oxidative stress-induced endothelial dysfunction in cardiovascular diseases","volume":"27","author":"A Shaito","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"pone.0349218.ref006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00395-024-01054-0","article-title":"The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity","volume":"120","author":"X Liu","year":"2025","journal-title":"Basic Res Cardiol"},{"issue":"8","key":"pone.0349218.ref007","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s11864-024-01238-9","article-title":"Precision treatment of anthracycline-induced cardiotoxicity: an updated review","volume":"25","author":"Z Kuang","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"pone.0349218.ref008","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/ard-2023-225406","article-title":"Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis","volume":"83","author":"J-W Kim","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0349218.ref009","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s10020-021-00358-4","article-title":"New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases","volume":"27","author":"W Chen","year":"2021","journal-title":"Mol Med"},{"issue":"7","key":"pone.0349218.ref010","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3390\/ph15070827","article-title":"Selective COX-2 inhibitors: road from success to controversy and the quest for repurposing","volume":"15","author":"AA El-Malah","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"pone.0349218.ref011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.therap.2023.10.008","article-title":"Drug-induced cardiac toxicity and adverse drug reactions, a narrative review","volume":"79","author":"A Destere","year":"2024","journal-title":"Therapie"},{"issue":"1","key":"pone.0349218.ref012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40360-024-00782-2","article-title":"Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS)","volume":"25","author":"S He","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"pone.0349218.ref013","doi-asserted-by":"crossref","first-page":"1127128","DOI":"10.3389\/fimmu.2023.1127128","article-title":"Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022","volume":"14","author":"Y Wang","year":"2023","journal-title":"Front Immunol"},{"key":"pone.0349218.ref014","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"F Zou","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0349218.ref015","doi-asserted-by":"crossref","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Z Cui","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0349218.ref016","first-page":"2982","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"GA Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"pone.0349218.ref017","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2021.15187","article-title":"Trends in cardiovascular risk factors in US adults by race and ethnicity and socioeconomic status, 1999-2018","volume":"326","author":"J He","year":"2021","journal-title":"JAMA"},{"issue":"19","key":"pone.0349218.ref018","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1002\/sim.9808","article-title":"Exact inference for fixed effects meta-analysis of 2\u2009\u00d7\u20092$$ 2\\times 2 $$ tables","volume":"42","author":"S Hansen","year":"2023","journal-title":"Stat Med"},{"issue":"1","key":"pone.0349218.ref019","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/toxsci\/kfae079","article-title":"In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessment","volume":"201","author":"MC Daley","year":"2024","journal-title":"Toxicol Sci"},{"issue":"21","key":"pone.0349218.ref020","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"C Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"pone.0349218.ref021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaccao.2022.12.007","article-title":"Screening for Coronary Artery Disease in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"R Velusamy","year":"2023","journal-title":"JACC CardioOncol"},{"key":"pone.0349218.ref022","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/DDDT.S479682","article-title":"Integrated Microbiome and Metabolome Analysis Reveals Correlations Between Gut Microbiota Components and Metabolic Profiles in Mice With Mitoxantrone-Induced Cardiotoxicity","volume":"19","author":"Q Zhang","year":"2025","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"pone.0349218.ref023","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"AA Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"key":"pone.0349218.ref024","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.hlc.2024.01.013","article-title":"Cancer therapies and cardiomyocyte viability: which drugs are directly cardiotoxic?","volume":"33","author":"L Balachandran","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"10126","key":"pone.0349218.ref025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"key":"pone.0349218.ref026","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cam4.5127","article-title":"Use of multikinase inhibitors\/lenvatinib in patients with high cardiovascular risk\/vasculopathy and radioiodine refractory-differentiated thyroid cancer","volume":"11","author":"P Jimenez-Fonseca","year":"2022","journal-title":"Cancer Med"},{"issue":"8","key":"pone.0349218.ref027","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials","volume":"147","author":"W Hou","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"pone.0349218.ref028","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/medicina58101475","article-title":"An update on the current and emerging use of thiazolidinediones for type 2 diabetes","volume":"58","author":"RV Giglio","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"pone.0349218.ref029","doi-asserted-by":"crossref","first-page":"112885","DOI":"10.1016\/j.ejmech.2020.112885","article-title":"Application of sulfoximines in medicinal chemistry from 2013 to 2020","volume":"209","author":"Y Han","year":"2021","journal-title":"Eur J Med Chem"},{"key":"pone.0349218.ref030","first-page":"2813","article-title":"Expression of concern: bombardier et al., \u201cComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,\u201d","volume":"353","author":"GD Curfman","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0349218.ref031","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"OP Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"pone.0349218.ref032","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/CIR.0000000000001139","article-title":"Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association","volume":"147","author":"LS Mehta","year":"2023","journal-title":"Circulation"},{"issue":"11","key":"pone.0349218.ref033","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Clinical Guidelines Committee of the American College of Physicians, Barry MJ, et al","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0349218.ref034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mayocp.2013.08.021","article-title":"Myocardial infarction risk among patients with fractures receiving bisphosphonates","volume":"89","author":"CB Pittman","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"pone.0349218.ref035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijcard.2016.04.088","article-title":"Adverse cardiovascular effects of nitrogen-containing bisphosphonates in patients with osteoporosis: a nationwide population-based retrospective study","volume":"215","author":"J-C Wang","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"pone.0349218.ref036","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.clinthera.2010.03.014","article-title":"Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis","volume":"32","author":"A John Camm","year":"2010","journal-title":"Clin Ther"},{"issue":"8","key":"pone.0349218.ref037","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/jbmr.3448","article-title":"Association of alendronate and risk of cardiovascular events in patients with hip fracture","volume":"33","author":"C-W Sing","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"12","key":"pone.0349218.ref038","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3390\/nu14122369","article-title":"Cardiovascular safety and effectiveness of bisphosphonates: from intervention trials to real-life data","volume":"14","author":"C Delli Poggi","year":"2022","journal-title":"Nutrients"},{"issue":"11","key":"pone.0349218.ref039","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1210\/jc.2013-1970","article-title":"Beneficial and adverse effects of testosterone on the cardiovascular system in men","volume":"98","author":"JB Ruige","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"pone.0349218.ref040","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","article-title":"Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis","volume":"13","author":"G Corona","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"pone.0349218.ref041","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/M19-0830","article-title":"Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American College of Physicians","volume":"172","author":"SJ Diem","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"pone.0349218.ref042","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jsxm.2018.04.641","article-title":"Testosterone and cardiovascular risk: meta-analysis of interventional studies","volume":"15","author":"G Corona","year":"2018","journal-title":"J Sex Med"},{"issue":"9","key":"pone.0349218.ref043","article-title":"Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study","volume":"132","author":"SY Loo","year":"2019","journal-title":"Am J Med"},{"key":"pone.0349218.ref044","article-title":"Androgens and cardiovascular disease in men.","volume-title":"Endotext","author":"BB Yeap","year":"2000"},{"key":"pone.0349218.ref045","article-title":"Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity","volume":"71","author":"JM Campistol","year":"2001","journal-title":"Transplantation"},{"key":"pone.0349218.ref046","doi-asserted-by":"crossref","first-page":"105466","DOI":"10.1016\/j.phrs.2021.105466","article-title":"Ferroptosis and its emerging roles in cardiovascular diseases","volume":"166","author":"N Li","year":"2021","journal-title":"Pharmacol Res"},{"issue":"1","key":"pone.0349218.ref047","doi-asserted-by":"crossref","first-page":"102882","DOI":"10.1016\/j.cpcardiol.2024.102882","article-title":"Doxorubicin and cyclophosphamide mode of chemotherapy-related cardiomyopathy: review of preclinical model","volume":"50","author":"A Avagimyan","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"pone.0349218.ref048","doi-asserted-by":"crossref","first-page":"930831","DOI":"10.3389\/fphar.2022.930831","article-title":"Vicious LQT induced by a combination of factors different from hERG inhibition","volume":"13","author":"X Xu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0349218.ref049","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM199607253350416","article-title":"Cisapride and fatal arrhythmia","volume":"335","author":"DK Wysowski","year":"1996","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0349218.ref050","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.3390\/cancers14246139","article-title":"Clinical effect of lenvatinib re-administration after transcatheter arterial chemoembolization in patients with intermediate stage hepatocellular carcinoma","volume":"14","author":"S Mawatari","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:29:28Z","timestamp":1780334968000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349218"}},"subtitle":[],"editor":[{"given":"Marina","family":"De Rui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349218","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}